Aptus Capital Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Aptus Capital Advisors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$59.1K	Buy	27,231 +621	+2%	+$1.54K	﹤0.01%	1254
2025 Q4	$47.9K	Buy	26,610 +883	+3%	+$1.8K	﹤0.01%	1297
2025 Q3	$57.1K	Buy	25,727 +874	+4%	+$1.42K	﹤0.01%	1213
2025 Q2	$36.8K	Buy	24,853 +915	+4%	+$1.87K	﹤0.01%	1214
2025 Q1	$61.3K	Buy	23,938 +575	+2%	+$1.37K	﹤0.01%	1082
2024 Q4	$43.9K	Buy	23,363 +1,026	+5%	+$1.45K	﹤0.01%	1124
2024 Q3	$22.8K	Buy	22,337 +1,412	+7%	+$1.49K	﹤0.01%	1020
2024 Q2	$24.5K	Buy	20,925 +1,304	+7%	+$1.54K	﹤0.01%	960
2024 Q1	$24.7K	Buy	19,621 +1,099	+6%	+$1.64K	﹤0.01%	949
2023 Q4	$33K	Buy	18,522 +1,025	+6%	+$1.59K	﹤0.01%	715
2023 Q3	$29K	Buy	17,497 +737	+4%	+$1.32K	﹤0.01%	728
2023 Q2	$33.5K	Buy	16,760 +750	+5%	+$1.79K	﹤0.01%	614
2023 Q1	$33.6K	Buy	+16,010	New	+$28.1K	﹤0.01%	595
2022 Q4	–	Sell	-13,957	Closed	-$15K	–	834
2022 Q3	$15K	Buy	13,957 +1,539	+12%	+$1.7K	﹤0.01%	635
2022 Q2	$14K	Buy	12,418 +967	+8%	+$1.13K	﹤0.01%	556
2022 Q1	$12K	Buy	+11,451	New	+$10.5K	﹤0.01%	595
2019 Q4	–	Sell	-3,638	Closed	-$7K	–	557
2019 Q3	$7K	Hold	3,638	–	–	﹤0.01%	446
2019 Q2	$17K	Buy	+3,638	New	+$15.4K	﹤0.01%	329

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Aptus Capital Advisors's PLX Position: Q1 2026 in Review

Aptus Capital Advisors increased its Protalix BioTherapeutics (PLX) stake by 2.3% in Q1 2026, buying an estimated $1.54K and bringing the position to 27,231 shares worth $59.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1254.

Aptus Capital Advisors first reported a position in PLX in Q2 2019 and has held it in 18 quarters since. The position peaked at $61.3K in Q1 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Aptus Capital Advisors held 27,231 shares of Protalix BioTherapeutics worth $59.1K as of Q1 2026.
Aptus Capital Advisors bought 621 Protalix BioTherapeutics shares in Q1 2026, an estimated $1.54K.
Protalix BioTherapeutics made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q1 2026, its #1254 holding.
Aptus Capital Advisors first reported a position in Protalix BioTherapeutics in Q2 2019 and has held it in 18 quarters since.
Aptus Capital Advisors's Protalix BioTherapeutics position peaked at $61.3K in Q1 2025.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Aptus Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.